Skip to main content

Table 4 Most common any grade (>10 % of patients) and grade ≥3 (>1 patient) drug-related AEs

From: Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

 

Chinese (n = 20)

Korean (n = 16)

Other (n = 7)

Overall (N = 43)

Any grade AE, n (%)

    

 Skin/subcutaneous tissue disordersa

10 (50)

4 (25)

7 (100)

21 (49)

 Diarrhea

10 (50)

4 (25)

3 (43)

17 (40)

 PN NECb

4 (20)

3 (19)

4 (57)

11 (26)

 Vomiting

4 (20)

3 (19)

2 (29)

9 (21)

 Neutropenia

3 (15)

4 (25)

1 (14)

8 (19)

 Thrombocytopenia

2 (10)

4 (25)

2 (29)

8 (19)

 Decreased appetite

5 (25)

0

3 (43)

8 (19)

 Fatigue

2 (10)

1 (6)

4 (57)

7 (16)

 Nausea

2 (10)

4 (25)

1 (14)

7 (16)

 Decreased platelet count

3 (15)

2 (13)

0

5 (12)

 Insomnia

3 (15)

0

2 (29)

5 (12)

Grade ≥3 AE, n (%)

    

 Neutropenia

3 (15)

4 (25)

1 (14)

8 (19)

 Thrombocytopenia

1 (10)

2 (25)

2 (29)

5 (12)

 Diarrhea

0

4 (25)

2 (29)

6 (14)

 Fatigue

1 (5)

1 (6)

2 (29)

4 (9)

 Anemia

1 (5)

0

2 (29)

3 (7)

 Hypokalemia

1 (5)

0

2 (29)

3 (7)

  1. AE adverse event, PN NEC peripheral neuropathy not elsewhere classified
  2. aSystem organ class, includes the preferred terms dry skin, macular rash, pruritus, skin hyperpigmentation (each n = 4), generalized pruritus, pruritic rash (each n = 3), maculopapular rash, skin exfoliation (each n = 2), skin discoloration, dermatitis acneiform, night sweats, drug eruption, papular rash, pigmentation disorder, and abnormal hair growth (each n = 1)
  3. bHigher level term, includes the preferred terms peripheral neuropathy (n = 9) and peripheral sensory neuropathy (n = 2)